{"product_id":"scph-vrio-analysis","title":"scPharmaceuticals Inc. (SCPH): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eCan scPharmaceuticals Inc. (SCPH) truly sustain its market advantage? This essential VRIO analysis distills whether its key assets possess the necessary Value, Rarity, Inimitability, and Organization to secure long-term success. Dive in now to reveal the definitive verdict on its competitive durability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 1. Proprietary Drug\/Device Combination Technology (FUROSCIX On-Body Infusor)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of scPharmaceuticals Inc.'s current valuation - the FUROSCIX On-Body Infusor system. It’s a classic pharma play: a known molecule delivered in a novel, patient-friendly way. The numbers from the second quarter of fiscal 2025 show the market is responding, but the clock is ticking on the device moat.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Addressing the Outpatient Diuresis Gap\u003c\/h3\u003e\n\u003cp\u003eThe value proposition is clear: convenient, subcutaneous delivery of furosemide outside the hospital setting. This directly addresses the unmet need for managing fluid overload without an IV line. The market validated this in Q2 2025, where net revenue hit \u003cstrong\u003e$16.0 million\u003c\/strong\u003e, nearly doubling the prior year's \u003cstrong\u003e$8.1 million\u003c\/strong\u003e. We shipped about \u003cstrong\u003e20,200\u003c\/strong\u003e doses that quarter. That’s real value creation right there.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the recent performance metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Value\u003c\/th\u003e\n\u003cth\u003eChange vs. Q2 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue (FUROSCIX)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e99%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Shipped\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e117%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e23%\u003c\/strong\u003e in Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides… the cash position at June 30, 2025, was only \u003cstrong\u003e$40.8 million\u003c\/strong\u003e, meaning this revenue needs to scale fast to cover operating burn.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Unique Delivery System\u003c\/h3\u003e\n\u003cp\u003eThe on-body infusor itself is rare in this specific indication. While furosemide is old news, the approved, ready-to-use device for subcutaneous administration is not something every competitor has on the shelf. Most alternatives involve older, more complex methods, which is why we are seeing adoption from approximately \u003cstrong\u003e4,700\u003c\/strong\u003e unique prescribers through Q2 2025.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability: Engineering vs. Molecule\u003c\/h3\u003e\n\u003cp\u003eImitability is moderate, and that’s the key risk. The device engineering, the manufacturing know-how, and the specific regulatory clearance for this combination are hard to replicate quickly. Still, the core drug, furosemide, is generic. If a larger player decides to invest heavily in a similar device platform, they could close the gap, though it would take time and regulatory hurdles.\u003c\/p\u003e\n\u003cp\u003eThe path to making it harder to copy centers on the next-gen tech:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003esNDA submission for the autoinjector is targeted for Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThis device promises to cut treatment time from five hours to under ten seconds.\u003c\/li\u003e\n\u003cli\u003eIt could slash Cost of Goods Sold (COGS) by \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization: Commercial Focus is Aligned\u003c\/h3\u003e\n\u003cp\u003eYes, the organization is clearly structured to push this product. The commercial team is focused on driving adoption among cardiologists and, more recently, nephrologists following the late April 2025 CKD launch. Sales to Integrated Delivery Networks (IDNs) grew \u003cstrong\u003e70%\u003c\/strong\u003e quarter-over-quarter in Q2 2025, showing the operational structure is effectively engaging large health systems.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Driven by Innovation Speed\u003c\/h3\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. It’s sustained only as long as the on-body infusor remains the most convenient option and before the next-generation autoinjector hits the market. The advantage is tied to execution speed. If the autoinjector SNDA submission slips past Q3 2025, the window for a sustained advantage narrows significantly as competitors watch the growth curve.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 2. Approved Indication Portfolio (Heart Failure and CKD)\n\u003c\/h2\u003e\n\u003cp\u003e\nFUROSCIX® (furosemide injection, \u003cstrong\u003e80 mg\/10 mL\u003c\/strong\u003e) is indicated for congestion due to fluid overload in adult patients with chronic heart failure and now chronic kidney disease (CKD).\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe dual-indication approval significantly expands the addressable patient pool. The FDA approval for the expanded CKD indication was on \u003cstrong\u003eMarch 6, 2025\u003c\/strong\u003e. The commercial launch into the CKD market occurred in late \u003cstrong\u003eApril 2025\u003c\/strong\u003e. The estimated total addressable market for FUROSCIX in the United States, targeting both chronic heart failure and CKD patients, is \u003cstrong\u003e$\\text{\\$12.5 billion}$\u003c\/strong\u003e. The CKD expansion targets an estimated \u003cstrong\u003e$\\text{700,000}$\u003c\/strong\u003e additional eligible patients.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nHaving a proven, approved product for fluid overload in both the heart failure and CKD patient groups is uncommon for a company of this size. CKD affects more than \u003cstrong\u003e$\\text{1 in 7}$\u003c\/strong\u003e U.S. adults.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nCompetitors can pursue similar indications, but the regulatory hurdles and clinical trial costs present significant barriers. The expansion required no additional clinical development costs, leveraging existing data for the sNDA.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe organizational structure demonstrates alignment through a clear commercial pivot.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe commercial strategy pivots to target nephrologists following the \u003cstrong\u003eApril 2025\u003c\/strong\u003e CKD launch.\u003c\/li\u003e\n\u003cli\u003eAs of the second quarter of 2025, approximately \u003cstrong\u003e$\\text{4,700}$\u003c\/strong\u003e unique prescribers had prescribed FUROSCIX.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe dual-indication status, once established, provides a broader commercial base that is difficult for a single-indication competitor to match quickly. The company was awarded \u003cstrong\u003e3-year exclusivity\u003c\/strong\u003e for subcutaneous administration of furosemide until \u003cstrong\u003eOctober 7, 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (HF Only - Pre-CKD)\u003c\/td\u003e\n\u003ctd\u003eValue (HF + CKD - Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFUROSCIX Net Revenue\u003c\/td\u003e\n\u003ctd\u003e$\\text{\\$3.8 million}$ (Q3 2023)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$\\text{\\$16 million}$\u003c\/strong\u003e (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Filled (Quarterly)\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for HF only period\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$\\text{20,200}$\u003c\/strong\u003e units (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Addressable Market Contribution\u003c\/td\u003e\n\u003ctd\u003eImplied portion of $\\text{\\$12.5 billion}$ TAM\u003c\/td\u003e\n\u003ctd\u003eCKD segment estimated at \u003cstrong\u003e$\\text{\\$3 billion}$\u003c\/strong\u003e at sNDA filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 3. Commercial Execution in Specialty Care (FUROSCIX Adoption)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated rapid market acceptance, shipping approximately \u003cstrong\u003e20,200\u003c\/strong\u003e doses in Q2 2025, representing a \u003cstrong\u003e117%\u003c\/strong\u003e annual growth rate over Q2 2024, indicating effective physician education and adoption following the late April 2025 launch into the chronic kidney disease (CKD) indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Achieving net FUROSCIX revenue of \u003cstrong\u003e$16.0 million\u003c\/strong\u003e in Q2 2025, a \u003cstrong\u003e99%\u003c\/strong\u003e year-over-year growth, suggests superior execution in a competitive landscape.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Commercial execution success is supported by specific channel performance metrics that are difficult to replicate without established infrastructure and knowledge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Leadership noted strong execution across commercial and operational fronts, leading to accelerating adoption, evidenced by key performance indicators.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Momentum relies on sustained marketing spend and physician engagement, with future advantage potentially tied to the Q3 2025 sNDA submission for the autoinjector.\u003c\/p\u003e\n\u003cp\u003eCommercial Execution Metrics Summary (FUROSCIX - Q2 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet FUROSCIX Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e99%\u003c\/strong\u003e increase over Q2 2024 ($8.1 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Shipped\/Filled\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e20,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e117%\u003c\/strong\u003e increase over Q2 2024 (9,300 doses)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequential Dose Growth (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e45%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eOver Q1 2025 (approx. 13,800 doses)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique Prescriber Count\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e4,700\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSince launch through end of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN Sales Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs. Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net (GTN) Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Q2 2025 (vs. 23% in Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational Strength Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCKD indication launch in late April 2025 saw adoption rates among nephrologists that were \u003cstrong\u003efaster\u003c\/strong\u003e than the initial heart failure uptake.\u003c\/li\u003e\n\u003cli\u003eThe Company reported a net loss of \u003cstrong\u003e$18.0 million\u003c\/strong\u003e for Q2 2025, while cash and cash equivalents stood at \u003cstrong\u003e$40.8 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe SCP-111 autoinjector, designed to reduce treatment time from five hours to less than ten seconds, remains on track for a supplemental New Drug Application (sNDA) submission in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eSales, General and Administrative expenses were \u003cstrong\u003e$21.2 million\u003c\/strong\u003e in Q2 2025, up from \u003cstrong\u003e$17.5 million\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 4. Pipeline Asset: Next-Generation Autoinjector (SCP-111)\n\u003c\/h2\u003e\n\u003cp\u003eThe SCP-111 program, which includes the ReadyFlow Autoinjector, represents a significant potential value driver for scPharmaceuticals Inc. by addressing the convenience and administration challenges associated with current furosemide delivery methods for edema management.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe SCP-111 program promises to cut administration time from an implied standard of up to five hours (for IV administration) to a single, subcutaneous injection of less than ten seconds, which is a massive patient convenience upgrade. The investigational formulation demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), which is well within the FDA's standard bioequivalence range of 80% to 125% when compared to intravenous furosemide. Furthermore, participants in the PK study reported a median pain score of 0 across all time points assessed.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eDeveloping a significantly faster, next-generation device for an existing drug via an sNDA pathway is a rare technological leap. The successful demonstration of bioequivalence to IV furosemide via a subcutaneous autoinjector is a notable achievement in drug-device combination development.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThis requires specialized device engineering and is protected by ongoing IP development. The Company has received five Notices of Allowance from the USPTO for patent applications covering the SCP-111 formulation, which will join four additional patents already owned, totaling nine potential patents covering the formulation once issued.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eBeing on track for a targeted supplemental New Drug Application (sNDA) filing in Q3 2025 shows R\u0026amp;D and regulatory teams are aligned and executing, despite an earlier timeline shift from late 2024. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026, for the accepted sNDA for the FUROSCIX ReadyFlow Autoinjector (SCP-111).\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained. If successful, this new device will create a significant, defensible moat against current FUROSCIX users and new entrants by offering superior patient convenience and rapid administration.\u003c\/p\u003e\n\n\u003cp\u003eKey Quantitative Data for SCP-111 Development:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration Time Goal\u003c\/td\u003e\n\u003ctd\u003eLess than 10 seconds\u003c\/td\u003e\n\u003ctd\u003eCompared to five hours for IV administration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioavailability (SCP-111 vs IV)\u003c\/td\u003e\n\u003ctd\u003e107.3% (90% CI: 103.9 - 110.8)\u003c\/td\u003e\n\u003ctd\u003eWithin FDA range of 80% to 125%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Pain Score (PK Study)\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003ctd\u003eAcross all time points assessed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget sNDA Filing\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eTargeted submission quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA Target Action Date\u003c\/td\u003e\n\u003ctd\u003eJuly 26, 2026\u003c\/td\u003e\n\u003ctd\u003eFor the accepted sNDA for the ReadyFlow Autoinjector.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patents Covering Formulation\u003c\/td\u003e\n\u003ctd\u003eNine (once issued)\u003c\/td\u003e\n\u003ctd\u003eFive recent Notices of Allowance joining four existing patents.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSupporting Study and Regulatory Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PK study was an open-label, single-center, single-dose, randomized, two-way crossover study involving twenty-one healthy volunteers.\u003c\/li\u003e\n\u003cli\u003eThe age range of study participants was 45 to 80 years.\u003c\/li\u003e\n\u003cli\u003eThe study compared SCP-111 to the equivalent dose of furosemide administered as two 40mg IV injections administered over 1-to-2 minutes, two hours apart.\u003c\/li\u003e\n\u003cli\u003eThe Company's market capitalization was reported as $255 million as of August 2025 news.\u003c\/li\u003e\n\u003cli\u003eNet FUROSCIX revenue for Q2 2025 was $16.0 million, representing approximately 99% annual growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 5. Focus on Cardiorenal Therapeutic Area Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep focus allows for specialized marketing, KOL development, and understanding of complex patient journeys (e.g., fluid overload in CKD\/HF).\u003c\/p\u003e\n\u003cp\u003eThe company's flagship product, FUROSCIX, is specifically indicated for edema due to fluid overload in adult patients with NYHA Class II and III chronic heart failure, with an expanded indication for chronic kidney disease (CKD) patients approved in March 2025, expected to be available by April 2025. The potential market for the CKD indication is estimated at $3 billion.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2024\u003c\/th\u003e\n\u003cth\u003eAnnual Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet FUROSCIX Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFUROSCIX Doses Filled\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e20,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e9,300\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e117%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e51.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Many large pharma companies cover this, but scPharmaceuticals Inc.’s exclusive focus provides a depth of knowledge.\u003c\/p\u003e\n\u003cp\u003eThe company's entire mission is dedicated to advancing care in the cardiorenal space through integrated solutions. The focus is on the intricate connections between the heart and kidneys for conditions like CKD and heart failure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Expertise is built over time through focused clinical trials and commercial experience in a niche area.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe FDA approval for the CKD indication required no additional clinical studies, suggesting the existing data and pharmacokinetic\/pharmacodynamic bridging strategy were sufficient, which is a result of focused development.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing an autoinjector designed to reduce treatment time from five hours to less than ten seconds.\u003c\/li\u003e\n\u003cli\u003eThe company reported approximately 4,700 unique prescribers since launch through the end of Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The entire mission is centered on cardiorenal care, ensuring resources aren't diluted across unrelated areas.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull Year 2024 Revenue was \u003cstrong\u003e$36.3 million\u003c\/strong\u003e, a \u003cstrong\u003e167%\u003c\/strong\u003e increase from the previous year.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$18.0 million\u003c\/strong\u003e for Q2 2025.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of June 30, 2025, were \u003cstrong\u003e$40.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSales to Integrated Delivery Networks increased \u003cstrong\u003e70%\u003c\/strong\u003e in Q2 2025 compared to Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Specialized focus builds reputation and trust with the target physician community, which is definitely hard to buy.\u003c\/p\u003e\n\u003cp\u003eThe expansion into the CKD market targets a patient population where CKD affects more than 1 in 7 U.S. adults.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 6. Established Supply Chain for On-Body Infusor Delivery\n\u003c\/h2\u003e\n\n\u003cp\u003eThe supply chain capability supports the commercialization of the drug\/device combination product, FUROSCIX.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAbility to manufacture or source sufficient quantities of both the drug and the complex on-body infusor to meet growing demand (e.g., approximately \u003cstrong\u003e20,200\u003c\/strong\u003e doses shipped in Q2 2025).\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Amount\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet FUROSCIX Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e99%\u003c\/strong\u003e over Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFUROSCIX Doses Filled\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e20,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e117%\u003c\/strong\u003e over Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of Product Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $2.3 million in Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net (GTN) Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e23%\u003c\/strong\u003e for Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. While many companies have supply chains, one optimized for a drug\/device combo like this is less common.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate. It requires validated third-party relationships and quality control systems for the device component.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe on-body infusor is a drug-device combination product.\u003c\/li\u003e\n\u003cli\u003eThe company is dependent on third parties to deliver sufficient quantities of supplies, components, and drug product.\u003c\/li\u003e\n\u003cli\u003eA supplemental New Drug Application (sNDA) for an autoinjector is on track for Q3 2025, which could reduce Cost of Goods Sold (COGS) by \u003cstrong\u003e70%\u003c\/strong\u003e to \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eAdequate. They noted they do not expect a material impact on supply chain costs, suggesting control, but success is still dependent on third parties.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of June 30, 2025, were \u003cstrong\u003e$40.8 million\u003c\/strong\u003e, down from \u003cstrong\u003e$75.5 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eSales to Integrated Delivery Networks increased \u003cstrong\u003e70%\u003c\/strong\u003e in Q2 2025 compared to Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. It’s a necessary operational capability, but not a source of sustained advantage unless they achieve significant, proprietary cost leadership.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 7. Market Access\/Reimbursement Strategy (Navigating Medicare Part D)\n\u003c\/h2\u003e\n\u003cp\u003eThe navigation of the Medicare Part D redesign, mandated by the Inflation Reduction Act (IRA), presents a critical component of SCPH's market access strategy, directly impacting net revenue realization and patient access.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eSuccessfully navigating the Medicare Part D redesign, which, despite increasing the gross-to-net discount to \u003cstrong\u003e27%\u003c\/strong\u003e in Q2 2025, is now creating favorable copay dynamics for patients. The company noted the GTN headwind from the Part D redesign, with the discount rising from approximately \u003cstrong\u003e23%\u003c\/strong\u003e in Q1 2025 to \u003cstrong\u003e27%\u003c\/strong\u003e in Q2 2025, and anticipated to approach \u003cstrong\u003e30%\u003c\/strong\u003e in Q3 2025. This near-term pressure is juxtaposed against longer-term tailwinds from lower patient out-of-pocket costs, with the annual beneficiary OOP cap set at \u003cstrong\u003e$2,000\u003c\/strong\u003e starting in 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net (GTN) Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected GTN Discount\u003c\/td\u003e\n\u003ctd\u003eApproaching \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 GTN Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Beneficiary OOP Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEffective 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturer Catastrophic Liability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 Redesign Mandate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet FUROSCIX Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.04M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Shipped\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Understanding and optimizing for complex payer dynamics like the IRA manufacturer rebate requirements is a specialized skill. The manufacturer liability shift includes mandated discounts of \u003cstrong\u003e10%\u003c\/strong\u003e during the coverage period and \u003cstrong\u003e20%\u003c\/strong\u003e during the catastrophic period for branded drugs under the new program.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. This is learned through direct experience and negotiation with payers over time. The company is actively monitoring CMS claims for patients in catastrophic coverage and utilizing hub services to alert patients about copay status.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. They are actively using the evolving copay paradigm to drive prescription growth, showing proactive management. The company noted an observable difference in the number of \u003cstrong\u003e$0\u003c\/strong\u003e copays in April and May 2025, contrasting with higher copays in January and February 2025, attributed to patients either enrolling in smoothing or reaching their out-of-pocket cap. This is cited as a significant driver for fill rate improvement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrescriber Growth: Approximately \u003cstrong\u003e3,100\u003c\/strong\u003e unique HCPs prescribed FUROSCIX as of the end of Q3 2024.\u003c\/li\u003e\n\u003cli\u003eDoses per Script: Averaged \u003cstrong\u003e7.4\u003c\/strong\u003e doses per script in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained. The ability to turn regulatory changes (like the IRA) into a patient benefit that drives volume is a powerful, ongoing skill. Management stated they are 'bullish on this quarter (Q2)' based on the observed inflection in volume starting in March and carrying through April and May 2025, expecting growth to outpace GTN headwinds.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 8. Sales Channel Penetration (IDN Growth)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDirect access to major hospital systems, with sales to Integrated Delivery Networks (IDNs) increasing \u003cstrong\u003e70%\u003c\/strong\u003e from Q1 to Q2 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet FUROSCIX Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFUROSCIX Doses Filled\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e13,800\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e20,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN Sales Growth (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e119%\u003c\/strong\u003e (vs Q4 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e (vs Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net (GTN) Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Direct IDN access is valuable and often requires long-term relationship building.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can hire reps, but breaking into established IDN formularies takes time.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. This growth shows the commercial team is successfully engaging large, organized healthcare systems.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCumulative unique prescribers reached approximately \u003cstrong\u003e4,700\u003c\/strong\u003e through the end of Q2 2025.\u003c\/li\u003e\n\u003cli\u003eNephrology adoption rate exceeded initial heart failure growth.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents stood at \u003cstrong\u003e$40.8 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. While valuable now, IDN contracts can shift, so this advantage needs constant reinforcement.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003escPharmaceuticals Inc. (SCPH) - VRIO Analysis: 9. Registered Intellectual Property Rights\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A portfolio of registered IP rights protecting the core technology and formulation, which is the foundation for future product exclusivity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. All pharma companies have IP, but the quality and breadth of the portfolio matter most.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Patents are legally granted monopolies; they are the definition of hard-to-imitate assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Assumed High. The company is actively developing new IP (SCP-111), indicating a commitment to protecting its assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Strong, broad IP provides the longest-lasting protection against generic or direct competition.\u003c\/p\u003e\n\u003ch3\u003eIntellectual Property Portfolio Metrics\u003c\/h3\u003e\n\u003cp\u003eThe intellectual property portfolio centers on the novel, pH-neutral furosemide formulation for subcutaneous administration, exemplified by the investigational autoinjector, SCP-111. This formulation demonstrated a bioavailability of \u003cstrong\u003e107.3%\u003c\/strong\u003e compared to intravenous (IV) furosemide in a pharmacokinetic study. The company's commitment to IP protection is evidenced by its pipeline development and patent grants related to the core technology.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP\/R\u0026amp;D Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal SCP-111 Formulation Patents (Issued + Allowed)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9\u003c\/strong\u003e (4 owned + 5 allowed)\u003c\/td\u003e\n\u003ctd\u003eAs of August 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patent Example (pH Range)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 to 8.5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatent No. 10272064\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patent Example (Tromethamine Conc.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25 mM to 150 mM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatent US12048709B2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCP-111 Bioavailability (vs. IV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e107.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePK Study Result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific granted patents cover the liquid pharmaceutical formulations, such as Patent No. \u003cstrong\u003e10272064\u003c\/strong\u003e, which specifies a pH in the range of \u003cstrong\u003e7 to 8.5\u003c\/strong\u003e and a tris(hydroxymethyl)aminomethane concentration greater than or equal to about \u003cstrong\u003e50 mM\u003c\/strong\u003e. Another granted patent, \u003cstrong\u003eUS12048709B2\u003c\/strong\u003e, details furosemide amounts from \u003cstrong\u003e10 mg to 200 mg\u003c\/strong\u003e and tromethamine concentrations between \u003cstrong\u003e25 mM and 150 mM\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eKey IP Milestones and Financial Context\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe core technology aims to deliver 'hospital-strength' diuresis for outpatient use with complete bioavailability of \u003cstrong\u003e99.65%\u003c\/strong\u003e when compared with intravenous administration.\u003c\/li\u003e\n\u003cli\u003eThe company received \u003cstrong\u003efive notices of allowance\u003c\/strong\u003e from the USPTO for SCP-111 formulation patent applications in August 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$4.1 million\u003c\/strong\u003e for the three months ended June 30, 2025, compared to \u003cstrong\u003e$2.7 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eAs of March 31, 2025, cash and cash equivalents were \u003cstrong\u003e$57.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516247236757,"sku":"scph-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/scph-vrio-analysis.png?v=1740213506","url":"https:\/\/dcf-model.com\/fr\/products\/scph-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}